Omega Diagnostics is expected to move into profit next year.
In the first half of this year, the allergy division increased its revenues by one-quarter, while the infectious disease division revenues fell by one-third. Food intolerance generates the majority of revenues and this division increased its revenues by 6% to £4.46m. Total group revenues from continuing operations were £5.23m.
VISITECT CD4 is expected to generate £500,000 in revenues this year and £2m in the year to March 2021. This provides the upside for the group.
© 2020 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.